Context Therapeutics (CNTX) has provided an update.
Context Therapeutics Inc. has announced the submission of an IND application to the FDA for a Phase 1 clinical trial of CTIM-76, an innovative treatment targeting CLDN6-positive tumors. This move marks a significant step in the company’s efforts to develop new cancer therapies and has the potential to generate interest among investors tracking advancements in the biopharmaceutical sector.
See more data about CNTX stock on TipRanks’ Stock Analysis page.
